
    
      Eligible patients will be randomized to treatment with either 1) open-label 3TC twice daily
      plus Viramune once daily for 2 weeks and then with Viramune twice daily; or 2) open label 3TC
      twice daily plus Viramune placebo once daily for 2 weeks and then twice daily Viramune.
      Patients will start Viramune and 3TC on study day 0. Patients will be evaluated for
      development of AIDS progression events at months 1, 2, 3, and 4, and every 2 months
      thereafter until 18 months after the last patient is enrolled or 24 months, whichever occurs
      first.
    
  